EP1353671A1 - Analogues de tacrolimus neurotrophiques - Google Patents

Analogues de tacrolimus neurotrophiques

Info

Publication number
EP1353671A1
EP1353671A1 EP01991558A EP01991558A EP1353671A1 EP 1353671 A1 EP1353671 A1 EP 1353671A1 EP 01991558 A EP01991558 A EP 01991558A EP 01991558 A EP01991558 A EP 01991558A EP 1353671 A1 EP1353671 A1 EP 1353671A1
Authority
EP
European Patent Office
Prior art keywords
compound
injury
nerve
spinal cord
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01991558A
Other languages
German (de)
English (en)
Other versions
EP1353671A4 (fr
Inventor
Nobuya Matsuoka
Takayuki Yamaji
Bruce Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of EP1353671A1 publication Critical patent/EP1353671A1/fr
Publication of EP1353671A4 publication Critical patent/EP1353671A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • This invention relates to a tacrolimus derivative having a high level of neurotrophic activity and a low level of immunosuppressive activity.
  • Certain macrolide compounds e.g. tacrolimus and related compounds, are known to help prevent or treat cerebral ischemia (WO94/14443).
  • Certain non-immunosuppressive compounds i.e., geldanamycin and its analogs, are shown to disrupt the steroid receptor complex and promote nerve growth (WO99/21552).
  • the present inventors have found that a particular tacrolimus analogue, i.e. Compound (I), mentioned below, has an excellent neurotrophic activity but, unlike tacrolimus, has little or no immunosuppressive activity.
  • Compound (I) exerts superior levels of neurotropic activity compared to tacrolimus, for instance, as measured by its ability to increase neurite length.
  • the administration of Compound (I) is shown to induce axonal regeneration and speed recovery from nerve crush or spinal cord injuries.
  • Compound (I) exerts these advantageous neurotropic effects with little or no immunosuppressive activity compared to tacrolimus.
  • the present invention provides new uses for Compound (I) as a superior neurotrophic agent, as well as a neurotropic agent with little or no immunosuppressive activity.
  • the invention provides a neurotrophic agent or composition that comprises Compound (I).
  • this invention provides a method for preventing or treating neuronal injury/dysfunction that comprises administering Compound (I) to a mammal.
  • Compound (I) is useful for ameliorating, preventing, or treating neurological injury or dysfunction caused by damage or injury to, deterioration of, or disease of the nervous system, while advantageously having little or no immunosuppressive effect.
  • Compound (I) is useful for treating damage, deterioration or dysfunction caused by physical injury, nutritional disorders, ischemia, degenerative diseases, malignant diseases, infectious diseases, and by drug interactions, toxins or poisons.
  • Compound (I) is useful for treating neurological damage or dysfunction caused by neurosurgery, peripheral nerve injury, burns, encephalomyelitis, HIV, herpes, cancer, radiation treatment, drug interaction, folic acid or Vitamin B-12 deficiency, and by exposure to neurotoxins or chemicals such us lead.
  • Compound (I) is useful for preventing or treating neuronal injury and dysfunction, such as polymyositis (multiple myositis), Guillan-Barre syndrome, Meniere's disease, polyneuritis (multiple neuritis), mononeuritis (solitary neuritis), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, radiculopathy, neuropathy (such as diabetic neuropathy, chemotherapy-induced neuropathy, etc.), spinal cord injury, senile dementia, vascular dementia, multiple sclerosis, physical palsy, etc.
  • neuronal injury and dysfunction such as polymyositis (multiple myositis), Guillan-Barre syndrome, Meniere's disease, polyneuritis (multiple neuritis), mononeuritis (solitary neuritis), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, radiculopathy, neuropathy (such as diabetic neuro
  • This compound may be produced as described by U.S. Patent 5,376,663, Example 29.
  • Compound (I) used in the present invention it is to be understood that there may be conformers and one or more stereoisomers, such as optical and geometrical isomers due to asymmetric carbon atom(s) or double bond(s), and such conformers and isomers are also included within the scope of the compound in the present invention.
  • Compound (I) may also be in the form of a pharmaceutically acceptable salt, derivative, solvate or pro-drug, all of which are included within the scope of the present invention.
  • the solvate preferably includes a hydrate and an ethanolate.
  • a preferable form of Compound (I) is the following one:
  • Compound (I) in the present invention may be administered as a pure compound or as a mixture with another compound or other ingredients, preferably, in a pharmaceutical vehicle or carrier.
  • a pharmaceutical vehicle or carrier When Compound (I) is used in the form of a pharmaceutical preparation or composition it may be admixed with an organic or inorganic carrier, vehicle or excipient suitable for external (topical), oral, enteral, subcutaneous, intravenous, intramuscular, or parenteral applications.
  • it may be present in solid, semisolid or liquid composition, which contains Compound (I) as an active ingredient and one or more carriers, vehicles or excipients.
  • Typical carriers, vehicles or excipients include, but are not limited to conventional pharmaceutical carriers, medicinal or pharmaceutical agents, buffers, dispersants, emulsifying agents and adjuvants.
  • Compound (I) may also be compounded with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, eye drops, suppositories, solutions (saline, for example), emulsions, suspensions (olive oil, for example), ointments, aerosol sprays, creams, skin plasters, patches and any other form suitable for use.
  • non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, eye drops, suppositories, solutions (saline, for example), emulsions, suspensions (olive oil, for example), ointments, aerosol sprays, creams, skin plasters, patches and any other form suitable for use.
  • Suitable carriers include water, aqueous saline and dextrose solutions, oils, including animal, vegetable and synthetic oils, and petroleum products.
  • Other useful carriers include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form.
  • stabilizing, emulsifying, thickening, coloring agents, flavoring agents, and perfumes may be used.
  • Compound (I) is included in the pharmaceutical composition in an amount effective to produce the desired effect upon a particular disease process or condition.
  • Compound (I) is included in an amount sufficient to provide a neurotropic effect or stimulate nerve cell growth.
  • Mammals which may be treated using the method of the present invention include livestock mammals such as cows, horses, pigs, etc., domestic animals such as dogs, cats, rats, mice, rabbits, hamsters, etc., primates, and humans.
  • Preferable modes for the administration or application of products or compositions containing Compound 1 to humans include injection or oral administration.
  • While the therapeutically effective amount or dosage of Compound (I) may vary among individual patients and also depends upon the age and condition of each individual patient to be treated, a daily dose ranging from about 0.0001-1000 mg, preferably 0.001-500 mg and more preferably 0.01-100 mg of the active ingredient is generally given for treating diseases, and an average single dose of about 0.001- O.Olmg, 0.2-0. 5 mg, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg and 500 mg is generally administered. Daily doses for chronic administration in humans will be in the range of about 0.1-30 mg/kg/day. Compound (I) may also be administered or applied simultaneously, separately or sequentially with other agents having neurotrophic or nerve cell growth stimulating activity.
  • compositions according to the invention can be periodically administered to a mammalian subject (e.g., a human patient), in need of such treatment, to promote neuronal regeneration and functional recovery and to stimulate neurite outgrowth and thereby to treat various neuropathological states, including damage to peripheral nerves and the central nervous system caused by physical injury (e.g., spinal cord injury and trauma, sciatic or facial nerve lesion or injury, limb transplantation following amputation); disease (e.g., diabetic neuropathy); cancer chemotherapy (e.g., neuropathy induced by acrylamide, taxol, vinca alkaloids and doxorubicin); sequela ⁇ e.g. allophasis (such as articulation disorders), clouding of consciousness, dyskinesia, etc.
  • a mammalian subject e.g., a human patient
  • neurological disorders including, but not limited to, various peripheral neuropathic and neurological disorders including, but not limited to: trigeminal neuralgia, glosspharyngeal neuralgia, Bell's palsy, myasthenia gravis, muscular dystrophy, amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar inherited muscular atrophy, herniated, ruptured or prolapsed vertebral disk syndromes, cervical spondylosis, plexus disorders, thoracic outlet destruction syndromes, peripheral neuropathies such as those caused by lead, acrylamides, gamma-diketones (glue-sniffer's neuropathy), carbon disulfide, dapsone, ticks, porphyria, Gullain-Barre syndrome, Alzheimer's disease, Parkinson's disease, and Huntington's chorea.
  • peripheral neuropathies such as those caused by lead, acrylamides, gamma-diketones (glue-sniffer's neuropathy
  • a transsection of a peripheral nerve or a spinal cord injury can be treated by administering a nerve growth stimulating amount of the agent to the mammal and grafting to the peripheral nerve or spinal cord a nerve graft such as an allograft (Osawa et al., J Neurocytol 19:833-849, 1990; Buttemeyer et al., Ann. Plastic Surgery 35:396-401, 1995) or an artificial nerve graft (Madison and Archibald, Exp. Neurol. 128:266-275, 1994; Wells et al., Exp. Neurol. 146:395-402, 1997).
  • a nerve graft such as an allograft (Osawa et al., J Neurocytol 19:833-849, 1990; Buttemeyer et al., Ann. Plastic Surgery 35:396-401, 1995) or an artificial nerve graft (Madison and Archibald, Exp. Neurol. 128:266-275, 1994; Wells
  • the space between the transected ends of the peripheral nerve or spinal cord is preferably filled with a non-cellular gap-filling material such as collagen, methyl cellulose, etc., or cell suspensions that promote nerve cell growth, such as Schwann cells (Xu et al., J. Neurocytol. 26:1-16, 1997), olfactory cells and sheathing cells (Li et al. Science 277:2000-2002, 1997).
  • the nerve growth promoting agent can be included together with such cellular or non-cellular gap-filling materials, or administered systemically before, during or after the nerve graft procedure.
  • compound (I) is useful for treating or preventing the neuronal injury/dysfunction polymyositis (multiple myositis), Guillain-Barre syndrome, Meniere's disease, polyneuritis (multiple neuritis), mononeuritis (solitary neuritis), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, radiculopathy, diabetic neuropathy, chemotherapy-induced neuropathy, senile dementia, vascular dementia, multiple sclerosis, physical palsy, or spinal cord injury.
  • neuronal injury/dysfunction polymyositis multiple myositis
  • Guillain-Barre syndrome Meniere's disease
  • polyneuritis multiple neuritis
  • mononeuritis solitary neuritis
  • Alzheimer's disease Parkinson's disease
  • ALS amyotrophic lateral sclerosis
  • radiculopathy diabetic neuropathy, chemotherapy-induced neuropathy, senile dementia, vascular dementia,
  • Example 1 Treatment with Compound (I) Significantly Increases Neurite Lengths of
  • Embryonic hippocampal neurons were obtained from rat pups on embryonic day 18.5 ("E18.5"), according to Banker and Cowan (Brain Research, 1977, 126: 397-425). Briefly, the hippocampal regions were removed, minced, and incubated in 100 LU. papain at 37°C for 45 min, and the cells were resuspended in complete neuronal medium: minimal essential medium without L-glutamine (GIBCO, Grand Island, NY), 1.5ml/100ml medium of high glucose minimal essential medium (GIBCO), O.lml/lOOml medium of serum extender (Hito + Tm; Collaborative Research Inc, Lexington, MA), glutamine (GIBCO), 5% fetal calf serum (GIBCO).
  • coverslips 500 cells/coverslip coated with poly-L-lysine.
  • the coverslips were inverted onto dishes that had been precoated with a monolayer of cortical astrocytes.
  • Hippocampal neurons (identified by their characteristic polarity and dendrites) were examined daily and randomly photographed (9-12 frames/coverslip) at 72 h. Axon (defined as the longest process) lengths were measured on photographic prints using a Houston Instrument HI-PAD digitizing tablet connected to an IBM XT computer with appropriate software (Bioquant IN, R & M Biometrics, Nashville, TN); only processes more than threefold of the cell body length were measured. Data from identically treated coverslips (three or four per group) were not different and therefore were combined. Mean values were calculated and compared using a one-way (groups treated with Compound (la) or tacrolimus versus an untreated control group) ANOVA followed by Newman-Kuels multiple comparisons test (WINKS 4.62 professional edition).
  • SH-SY5 Y human neuroblastoma cells were maintained in DMEM medium (GIBCO) supplemented with 10% fetal calf serum (SIGMA), 501.U./ml of penicillin, and 50 ⁇ g/ml streptomycin (GIBCO) at 37°C in 7% CO 2 .
  • Cells were plated in six-well plates at 15,000 cells/well and treated with 0.4 ⁇ M aphidicolin (SIGMA). At 5 days, cells were washed and treated with nerve growth factor (NGF) at 10 ng/ml (to induce process outgrowth) in the presence or absence of tacrolimus (10 nM) or Compound (la) (1 nM).
  • NGF nerve growth factor
  • Compound (la) was dissolved in vehicle comprising 30% dimethylsulfoxide (DMSO):70% saline.
  • vehicle comprising 30% dimethylsulfoxide (DMSO):70% saline.
  • Three axotomized rats received subcutaneous daily injections either Compound (la) (1 or 5 mg/kg) or an equivalent volume of vehicle (30% DMSO in saline) (5 l/kg)
  • the rats were deeply anesthetized with 4% halothane, heparinized, and perfused with 4% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4) for 10s followed by 5% glutaraldehyde (1L) in 0.1 M sodium phosphate buffer (pH 7.4) and fixed at 4°C for 24 h.
  • Tissues were sampled from the sciatic nerve at a known (5 mm) distance from the crush site. In the present study, only the data from the branch of the posterior tibial nerve supplying the soleus muscle are reported.
  • Tissues were placed in 0.1 M sodium phosphate buffer (pH 7.4), postfixed with 1% osmium tetroxide (in 0.1 M phosphate buffer) for 2.5 h, dehydrated in ethanol and embedded in plastic. Semithin sections were stained with uranyl acetate and lead citrate, mounted on film-supported 75 mesh grids, and examined in a JEOL 100 CX electron microscope.
  • mean values for recovery of function were compared using one-way ANOVA followed by the Newman-Keuls multiple comparisons test for comparison of individual values.
  • mean values for the number of axons were compared using one-way ANOVA followed by the Newman Keuls multiple comparisons test for comparison of individual values.
  • Morphological examination of the animals was conducted at 18 days following axotomy.
  • Compound (la) was dissolved in vehicle comprising 30% dimethylsulfoxide (DMSO): 10% saline.
  • vehicle comprising 30% dimethylsulfoxide (DMSO): 10% saline.
  • the spinal cord lesioned rats received subcutaneous daily injections the Compound (la) (2 mg/kg) or an equivalent volume of vehicle (30% DMSO in saline) (5ml/kg) for seven weeks following the surgery. Evaluation of functional recovery
  • Rats were allowed to move freely in an open field for 1 min and rated 0-6 according to the scale presented below.
  • Rats were tested on wooden beams (1.5m long) with decreasing width: 7.7cm, 4.7cm, 2.7cm and 1.7cm. Rats were allowed to walk on the bars, and the narrowest bar they could walk on without any slips in at least two trails was recorded.
  • the hind limbs of rats were inked and footprint were made on paper covering a narrow runway of 60cm length and 7.5cm width. A series of at least six sequential steps was used to determine the 5 -point footprint score. 0: Constant dorsal stepping or hind limb dragging, i.e. no footprint is visible
  • Example 5 Compound (la) Binds to FKBP12. but Unlike Tacrolimus Exerts Little or No
  • the binding assay was performed according to a similar manner to that of Tamura, K., et al (Biochemical arid Biophysical Research Communications, Vol. 202, No. 1, 437-499, 1994). The results are shown in Table 8.
  • Compound (I) provides a potent neurotrophic or nerve cell growth stimulating activity, though it has no immunosuppressive activity. Accordingly, the present invention provides a useful neurotrophic agent for stimulating or promoting neuronal growth or regeneration, particularly when an immunosuppressive effect is not advantageous or desired.
  • An article of manufacture comprising packaging material and Compound (I) identified in the above contained within said packaging material, wherein said Compound (I) is therapeutically effective for preventing or treating neuronal dysfunction, and wherein said packaging material comprises a label or a written material which indicates that Compound (I) can or should be used for preventing or treating neuronal injury/dysfunction.
  • a commercial package comprising the pharmaceutical composition containing Compound (I) identified in the above and a written matter associated therewith, wherein the written matter states that Compound (I) can or should be used for preventing or treating neuronal injury/dysfunction.
  • compositions such as a cell suspension, tissue, or graft comprising a cell treated with Compound (I).
  • Such compositions are useful for repairing damage to the nervous system.
  • Such compositions may also include other nerve cell growth stimulating agents, such as other types of cell suspensions that promote or assist nerve cell growth, such as myelin- producing cells such as Schwann cells or oligodendrocytes, glial cells and sheathing cells; extracellular matrix material, such as collagen; or other specific neuroregulators such as cytokines, mitogenic factors, immunophilins, and neurotrophins, such as NGF-1, BDNF, CNTF, NT-3, NT-4 and NT-5.
  • nerve cell growth stimulating agents such as other types of cell suspensions that promote or assist nerve cell growth, such as myelin- producing cells such as Schwann cells or oligodendrocytes, glial cells and sheathing cells; extracellular matrix material, such as collagen; or other specific neuroregulators such as cytokines,
  • Grafts such as homografts, allografts or xenografts may also be treated with Compound (I) in order to facilitate neuronal outgrowth and their use as transplants and for other applications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Packages (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des dérivés de tacrolimus présentant des niveaux élevés d'activité neurotrophique et de faibles niveaux d'activité immunosuppressive. Ces composés constituent des agents neurotrophiques très utiles, en particulier dans la prévention ou le traitement d'une lésion/dysfonction neuronale.
EP01991558A 2000-12-29 2001-12-31 Analogues de tacrolimus neurotrophiques Withdrawn EP1353671A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25850000P 2000-12-29 2000-12-29
US258500P 2000-12-29
PCT/US2001/050419 WO2002053159A1 (fr) 2000-12-29 2001-12-31 Analogues de tacrolimus neurotrophiques

Publications (2)

Publication Number Publication Date
EP1353671A1 true EP1353671A1 (fr) 2003-10-22
EP1353671A4 EP1353671A4 (fr) 2004-07-14

Family

ID=22980816

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01991558A Withdrawn EP1353671A4 (fr) 2000-12-29 2001-12-31 Analogues de tacrolimus neurotrophiques

Country Status (18)

Country Link
EP (1) EP1353671A4 (fr)
JP (1) JP2004527472A (fr)
KR (2) KR100794204B1 (fr)
CN (1) CN1293877C (fr)
AR (1) AR035411A1 (fr)
AU (1) AU2002231277B2 (fr)
BR (1) BR0116762A (fr)
CA (1) CA2433384A1 (fr)
CZ (1) CZ20032060A3 (fr)
HU (1) HUP0302521A3 (fr)
IL (1) IL156664A0 (fr)
MX (1) MXPA03005941A (fr)
NO (1) NO20032913D0 (fr)
NZ (1) NZ527209A (fr)
PL (1) PL366301A1 (fr)
RU (1) RU2288716C2 (fr)
WO (1) WO2002053159A1 (fr)
ZA (1) ZA200305806B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
CA2554045A1 (fr) * 2004-01-20 2005-07-28 Astellas Pharma Inc. Methode de traitement des troubles de l'erection
EP1810675A1 (fr) * 2006-01-18 2007-07-25 Institut Curie Methode de traitement de la maladie de Huntington par l'inhibition de la dephosphorylation de la S421
JP2009102226A (ja) * 2006-02-14 2009-05-14 Meiji Milk Prod Co Ltd 脊髄損傷治療剤
JP5878015B2 (ja) * 2008-07-23 2016-03-08 ノバルティス アーゲー スフィンゴシン一リン酸受容体調節因子および筋肉炎症を治療するためのその使用
EP2817009A1 (fr) * 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Inhibiteurs de la calcineurine destinés à être utilisés dans le traitement des troubles vestibulaires entraînant des lésions
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323042A1 (fr) * 1987-12-09 1989-07-05 FISONS plc Procédé pour macrolides
WO1993014771A1 (fr) * 1992-02-01 1993-08-05 Fisons Plc Composes macrocycliques servant au traitement prophylactique du sida
WO1994004148A1 (fr) * 1992-08-25 1994-03-03 Fisons Plc Utilisation de composes de la classe des macrolides dans le traitement de maladies entrainant une obstruction reversible des voies aeriennes
WO2001005385A2 (fr) * 1999-07-21 2001-01-25 Fujisawa Pharmaceutical Co Ltd Nouvelle utilisation d'un compose de macrolide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
US5541193A (en) * 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323042A1 (fr) * 1987-12-09 1989-07-05 FISONS plc Procédé pour macrolides
WO1993014771A1 (fr) * 1992-02-01 1993-08-05 Fisons Plc Composes macrocycliques servant au traitement prophylactique du sida
WO1994004148A1 (fr) * 1992-08-25 1994-03-03 Fisons Plc Utilisation de composes de la classe des macrolides dans le traitement de maladies entrainant une obstruction reversible des voies aeriennes
WO2001005385A2 (fr) * 1999-07-21 2001-01-25 Fujisawa Pharmaceutical Co Ltd Nouvelle utilisation d'un compose de macrolide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOLD B G: "NEUROIMMUNOPHILIN LIGANDS: EVALUATION OF THEIR THERAPEUTIC POTENTIAL FOR THE TREATMENT OF NEUROLOGICAL DISORDERS" EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 9, no. 10, 2000, pages 2331-2342, XP001011856 ISSN: 1354-3784 *
See also references of WO02053159A1 *
STEINER ET AL: "Neurotrophic actions of non-immunosuppressive analogs of immunosuppressive drugs FK506, rapamycin and cyclosporin A" NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 3, no. 4, April 1997 (1997-04), pages 421-428, XP002125244 ISSN: 1078-8956 *

Also Published As

Publication number Publication date
BR0116762A (pt) 2004-08-10
KR20040007431A (ko) 2004-01-24
AR035411A1 (es) 2004-05-26
KR20070030331A (ko) 2007-03-15
RU2003123493A (ru) 2005-01-20
MXPA03005941A (es) 2005-02-14
CA2433384A1 (fr) 2002-07-11
HUP0302521A3 (en) 2007-03-28
AU2002231277B2 (en) 2006-11-30
HUP0302521A2 (hu) 2003-11-28
ZA200305806B (en) 2005-01-26
CN1293877C (zh) 2007-01-10
WO2002053159A1 (fr) 2002-07-11
CN1538843A (zh) 2004-10-20
NZ527209A (en) 2005-09-30
KR100794204B1 (ko) 2008-01-14
JP2004527472A (ja) 2004-09-09
PL366301A1 (en) 2005-01-24
EP1353671A4 (fr) 2004-07-14
IL156664A0 (en) 2004-01-04
CZ20032060A3 (cs) 2004-01-14
NO20032913D0 (no) 2003-06-24
RU2288716C2 (ru) 2006-12-10

Similar Documents

Publication Publication Date Title
Gaviria et al. Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats
Gold et al. The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury
Yin et al. Taxol-modified collagen scaffold implantation promotes functional recovery after long-distance spinal cord complete transection in canines
Geisler et al. GM-1 ganglioside in human spinal cord injury
MX2009002063A (es) Tratamiento de desordenes en cartilagos con factor de crecimiento de fibroblastos-18.
CH689541A5 (de) Inhibitoren der Enzymaktivität von Rotamase.
DE69635754T2 (de) Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe
AU1668599A (en) Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
AU2002231277B2 (en) Neurotrophic tacrolimus analogs
AU2002231277A1 (en) Neurotrophic tacrolimus analogs
US20040077676A1 (en) Neurotrophic tacrolimus analogs
Alvarez et al. Hippocampal histamine receptors: possible role on the mechanisms of memory in the rat, II
y Ribotta et al. Strategies for regeneration and repair in spinal cord traumatic injury
US6284771B1 (en) Method for treating schizophrenia
DE69531166T2 (de) Arzneistoff zur erleichterung der durch immunsuppressiva verursachten nebenwirkungen
JP2009504636A (ja) 血漿または血清を含む神経損傷治療用の医薬組成物
Itoh et al. The effect of neurotrophic pyrimidine heterocyclic compounds, MS-818 and MS-430, on the regeneration of injured peripheral nerves
DE60110247T2 (de) Angiogenische Tri- oder Tetrapeptide abgeleitet von AcSDKP
CA2455896A1 (fr) Utilisation de composes permettant de traiter des affections consecutives a une lesion du nerf corneen apres un lasik ou d'autres traumatismes ou chirurgies de l'oeil
US6476001B1 (en) Facilitation of repair of neural injury with CM101/GBS toxin
US6852496B1 (en) Methods of screening for agents that promote nerve cell growth
US20040162315A1 (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma
EP3362059B1 (fr) Nouvelles thérapies combinées pour le traitement de lésions neurologiques
CN1270727C (zh) 一种治疗脊髓损伤的治疗剂
KR20200101948A (ko) 신경계 질환 치료제

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040528

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 25/28 B

Ipc: 7A 61P 25/00 B

Ipc: 7A 61K 31/436 A

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1059891

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASTELLAS PHARMA INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091121

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1059891

Country of ref document: HK